| Ytd | -43.83% | |
| 1y | -28.02% |
| Open | 46.66 | Prev Close | 46.75 | Low | 44.29 | High | 46.75 | Mkt Cap | 7.39B |
| Vol | 7.37M | Avg Vol | 3.53M | EPS | -3.48 | P/E | N/A | Forward P/E | -39.95 |
| Beta | 0.42 | Short Ratio | 9.20 | Inst. Own | 110.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 55.97 | 200-d Avg | 72.18 | 1yr Est | 83.82 |
IONS News
Ionis has six commercial therapies, mostly focused on rare diseases. Zanvastro treats Alexander dise
Ionis Pharmaceuticals NASDAQ: IONS CEO Brett Monia outlined recent regulatory wins, commercial-launc
Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conferen
Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy
Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and
Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweigh
Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown
Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutra
Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings larg
BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Pe
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endp
Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impac
Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy a
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS)
NVS: -13% | Novartis shares are trading lower after the company announced the pelacarsen phase III L
Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascul
Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and mai
BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Pe
FDA approves Zanvastro from Ionis Pharmaceuticals as the first disease-modifying treatment for rare
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS)
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS)